Latest Nicholas J. Vogelzang Stories
Appointees join Caris' distinguished clinical and scientific team to accelerate the development and commercialization of innovative precision medicine technologies IRVING,
Two Studies Presented at 2014 AUA Annual Meeting SAN DIEGO, May 20, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced the presentation of data showing that its Decipher®
LONDON, May 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Third Phase 3 Trial of Custirsen to Receive FDA Fast Track Designation BOTHELL, Wash.
WHIPPANY, N.J., April 2, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.
BOTHELL, Wash. and VANCOUVER, British Columbia, Feb. 11, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 3, 2014 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., today announced the appointment of distinguished breast cancer specialist, George W.
International studies demonstrate importance of comprehensive tumor profiling for poor-prognosis cancer patients IRVING, Texas, Jan.
Studies address technical sensitivity, specificity, pharmacodynamics, heterogeneity and patient selection relevant to prostate cancer patient management SAN DIEGO and SAN FRANCISCO, Jan.
EAST SETAUKET, N.Y., Jan. 7, 2014 /PRNewswire/ -- John S. Kovach, M.D., President and CEO, Lixte Biotechnology Holdings, Inc. (LIXT.PK), announces the appointment of Daniel D.
- A serpent whose bite was fabled to produce intense thirst.